Publications by authors named "B K Michelsen"
Article Synopsis
- - The research aimed to assess data collection practices for non-musculoskeletal manifestations (NMMs), comorbidities, and safety outcomes in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) across 17 European registries, emphasizing the need for international collaboration for better treatment strategies.
- - A comprehensive survey with over 4,400 questionnaire items examined how 58 defined conditions were recorded in each registry, focusing on recording methods and the ability to link data to national registries.
- - The study found that while many registries recorded a variety of conditions consistently, Nordic countries showed potential for data linkage but had limited recording practices, while other regions maintained thorough documentation, paving the way
Article Synopsis
- The study aimed to evaluate the retention rates and remission outcomes of patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who started treatment with secukinumab over 24 and 48 months.
- Data was collected from 13 European registries, revealing that retention rates were around 51%-64%, and patients with no prior biologic treatments showed better outcomes compared to those with previous treatments.
- The findings suggest that secukinumab remains effective over four years, with higher success rates in treatment-naïve patients compared to those who had already tried other therapies.
Objectives: To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-offs in a large contemporary cohort.
Methods: Data from 2939 patients with axial spondyloarthritis (axSpA) starting their first tumour necrosis factor inhibitor in nine European registries were pooled and analysed. Receiver operating characteristic analyses were performed to identify cut-offs against external criteria.
Objective: Interstitial lung disease (ILD) is one of the most common pulmonary manifestations of rheumatoid arthritis (RA), but its prevalence has not been investigated in psoriatic arthritis (PsA). The role of methotrexate (MTX) in ILD development remains under debate. This study (1) compares the incidences of ILD in patients with RA or PsA initiating a first biologic disease-modifying antirheumatic drug (bDMARD) to that in the general population, and (2) investigates the role of MTX comedication on ILD incidence.
View Article and Find Full Text PDF